Key facts
- This page summarizes PERCEPTIVE ADVISORS LLC's Form 4 filing for Astria Therapeutics, Inc. (ATXS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 05 Feb 2024, 17:02.
PERCEPTIVE ADVISORS LLC - 01 Feb 2024 Form 4 Insider Report for Astria Therapeutics, Inc. (ATXS)
- Reporting relationship
- Director
- Issuer ticker
- ATXS
- Reported as of
- 01 Feb 2024
- Net transaction value
- +$29,999,522
- SEC form
- 4
- Accepted by SEC
- 05 Feb 2024, 17:02:33 UTC
- Prior SEC filing
- 12 Jan 2024
- Next SEC filing
- 20 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joseph Edelman - for Perceptive Advisors LLC, By: Joseph Edelman, its managing member
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
PERCEPTIVE ADVISORS LLC filed Form 4 for Astria Therapeutics, Inc. (ATXS) on 05 Feb 2024.
Change
- Previous filing in this sequence was filed on 12 Jan 2024.
- Current net transaction value: +$29,999,522.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATXS
transaction
Common Stock
Purchase
- Transaction value
- $29,999,522
- Shares
- +2,481,350
- Change %
- +104%
- Price
- $12.09
- Shares after
- 4,873,721
- Date
- 01 Feb 2024
- Ownership
- See footnote
- Footnotes
- F1
ATXS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,611,699
- Date
- 01 Feb 2024
- Ownership
- See footnote
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the :Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Footnote F2
The securities are directly held by Perceptive Xontogeny Ventures, L.P. ("PXV"). The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.